The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

By  

Current Cardiology Reviews, Vol. 4, Iss. 4, 2008-11 ,pp. : 293-299

Bentham Science Publishers

Access to resources Recommend Favorite

Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase

By Meyners W.  

Zeitschrift für Kardiologie, Vol. 93, Iss. 5, 2004-05 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?

By  

Current Vascular Pharmacology, Vol. 10, Iss. 4, 2012-07 ,pp. : 443-447

Bentham Science Publishers

Access to resources Recommend Favorite

Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction

By Berger Jeffrey   Brown David  

Journal of Thrombosis and Thrombolysis, Vol. 21, Iss. 3, 2006-06 ,pp. : 229-234

Springer Publishing Company

Access to resources Recommend Favorite

Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 11, Iss. 2, 2013-01 ,pp. : 89-95

Bentham Science Publishers

Access to resources Recommend Favorite